IMPORTANCE OF THE FIELD: Castrate-resistant prostate cancer continues to be inadequately addressed by currently available therapies. AREAS COVERED IN THIS REVIEW: This review will discuss recent developments, including new chemotherapies and chemotherapy regimens, antiangiogenic therapy, immunotherapy, and other new agents, such as endothelin-A receptor antagonists and clusterin inhibitors. WHAT THE READER WILL GAIN: The reader will gain an understanding of the therapies in development for castration-resistant disease. TAKE HOME MESSAGE: Therapies focused on multiple different targets are currently being studied for castrate-resistant prostate cancer.
No takes yet. Share an insight, caveat, or question.
Harzstark et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: